Antidiabetic mutation

In the course of a study devoted to the study of various variants of the SGLT1 gene (sodium-dependent glucose cotransporter 1, sodium-dependent glucose cotransporter 1) and their clinical manifestations, a missense mutation was discovered (a point mutation, as a result of which the modified codon begins to encode another amino acid) associated with a slowdown in glucose metabolism in the intestine. The risk of developing diabetes, obesity, and cardiovascular diseases in carriers of this mutation is lower than in those with other genetic variants.

The study involved 8,478 people, based on their genetic material, the relationship between mutations in the SGLT1 gene and cardiometabolic disorders was evaluated. The testing took place within the framework of The ARIC clinical trials (The Atherosclerosis Risk in Communities Study – A study of the Risk of Atherosclerosis in Communities) and lasted 25 years. About 6 percent of the subjects were carriers of this mutation, and among them there was a lower incidence of type 2 diabetes, obesity, as well as lower mortality rates, even after adjusting for the type of diet.

It turned out that carriers of the mutation tolerate a high-carbohydrate diet better, since much less glucose is absorbed in their intestines. The menu with such a diet includes pasta, bread, cookies, sugar-containing dishes.

Scientists believe that selective blocking of the SGLT-1 receptor may allow to slow down the absorption of glucose. This can form the basis of therapeutic techniques aimed at the prevention or treatment of cardiometabolic diseases and their consequences.

Article by Seidelmann et al. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk are published in the Journal of the American College of Cardiology.

Anastasia Poznyak, portal "Eternal Youth" http://vechnayamolodost.ru / based on the materials of the National Heart, Lung and Blood Institute: Gene mutation points to a new way to fight diabetes, obesity, heart disease.